Phaseline

Targets › NAPRT1

NAPRT1 (Nicotinate phosphoribosyltransferase): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Other.

Catalyzes the first step in the biosynthesis of NAD from nicotinic acid, the ATP-dependent synthesis of beta-nicotinate D-ribonucleotide from nicotinate and 5-phospho-D-ribose 1-phosphate. Helps prevent cellular oxidative stress via its role in NAD biosynthesis. (UniProt, Q6XQN6)

Open in Phaseline: the race on NAPRT1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
ChromaDexNiagen® Plus
Nicotinamide riboside (NR) precursor; boosts NAD+ biosynthesis via salvage pathway
NAPRT1Phase 1Healthy Volunteer–

Conditions

Healthy Volunteer (1)

Modalities

small molecule (1)

Companies

ChromaDex (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.